Endothelin and diabetic complications: a brain-centric view
Language English Country Czech Republic Media print
Document type Journal Article, Review
PubMed
29947530
DOI
10.33549/physiolres.933833
PII: 933833
Knihovny.cz E-resources
- MeSH
- Endothelin A Receptor Antagonists administration & dosage metabolism MeSH
- Endothelin B Receptor Antagonists administration & dosage metabolism MeSH
- Endothelins agonists antagonists & inhibitors metabolism MeSH
- Diabetes Complications drug therapy metabolism MeSH
- Humans MeSH
- Brain drug effects metabolism MeSH
- Cerebrovascular Circulation drug effects physiology MeSH
- Receptor, Endothelin A metabolism MeSH
- Receptor, Endothelin B metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Endothelin A Receptor Antagonists MeSH
- Endothelin B Receptor Antagonists MeSH
- Endothelins MeSH
- Receptor, Endothelin A MeSH
- Receptor, Endothelin B MeSH
The global epidemic of diabetes is of significant concern. Diabetes associated vascular disease signifies the principal cause of morbidity and mortality in diabetic patients. It is also the most rapidly increasing risk factor for cognitive impairment, a silent disease that causes loss of creativity, productivity, and quality of life. Small vessel disease in the cerebral vasculature plays a major role in the pathogenesis of cognitive impairment in diabetes. Endothelin system, including endothelin-1 (ET-1) and the receptors (ET(A) and ET(B)), is a likely candidate that may be involved in many aspects of the diabetes cerebrovascular disease. In this review, we took a brain-centric approach and discussed the role of the ET system in cerebrovascular and cognitive dysfunction in diabetes.
References provided by Crossref.org
